VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

Influenza virus CTA1-3M2e-DD protein vaccine
Vaccine Information
  • Vaccine Name: Influenza virus CTA1-3M2e-DD protein vaccine
  • Target Pathogen: Influenza virus
  • Target Disease: Influenza (flu)
  • Vaccine Ontology ID: VO_0002980
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: Influenza A virus (A/Puerto Rico/8/34(H1N1)) matrix protein 2 (M2)
  • M2 from Influenza A virus (A/Puerto Rico/8/34(H1N1)) gene engineering:
    • Type: Recombinant protein preparation
    • Description: The fusion proteins were expressed in E. coli DH5 cells, transformed with the expression vectors for the CTA1-DD, CTA1-M2e-DD or the CTA1-3M2e-DD fusion proteins, and grown in 500 ml cultures over night in SYPPG medium with 100 μg/ml carbenicillin, at 37 °C. The cells were harvested by centrifugation and the fusion proteins, produced as inclusion bodies, were washed before extraction by treatment with 8 M urea. After refolding the proteins by slowly diluting them 35–40x in Tris–HCl pH 7.4 at +4 °C, the fusion proteins were purified in two steps, by ion exchange and size exclusion chromatography. After concentration and sterile filtration the purified fusion proteins were stored in PBS at −80 °C until use (Eliasson et al., 2008).
    • Detailed Gene Information: Click Here.
  • Adjuvant: Cholera toxin A1-subunit-ProteinA D-fragment fusion protein
  • Immunization Route: Intranasal
Host Response

Mouse Response

  • Host Strain: BALB/c
  • Vaccination Protocol: Age- and sex matched mice were immunized intranasally (i.n.) twice, 3 weeks apart, with 20–50 μl containing 10 μg of the M2e-HBc particle 1818 admixed with 5 μg CTA1-DD-adjuvant, 10 μg of HBc admixed with 5 μg CTA1-DD-adjuvant, a range of doses as indicated were tested; CTA1-M2e-DD, CTA1-3M2e-DD (carrying three copies of M2e), CTA1-DD adjuvant alone or PBS. Groups with 3–12 individuals in each experiment were used as indicated (Eliasson et al., 2008).
  • Challenge Protocol: Challenge experiments were performed in Ghent. Before the first, and 2 weeks after each immunization, blood samples were collected from the ventral tail vein. The final bleeding of surviving mice was performed 2 weeks after challenge (Eliasson et al., 2008).
  • Efficacy: A targeted fusion protein based on the CTA1-DD adjuvant and containing tandem repeats of the matrix protein 2 (M2e) ectodomain epitope derived from Influenza A virus (A/Puerto Rico/8/34(H1N1)), CTA1-3M2e-DD, confers strong protective immunity against a potentially lethal challenge infection with influenza virus in mice. The formulation was highly effective for mucosal immunizations and promoted high M2e-specific serum IgG and mucosal IgA antibody titers and an hitherto unknown anti-M2e CD4 T cell immunity (Eliasson et al., 2008).
  • Host IgA response
    • Description: The CTA1-3M2e-DD construct stimulated significant anti-M2e IgA antibody titers in bronchial lavage. By contrast, soluble M2e-peptide, given even at high doses, 100 μg, together with CTA1-DD (WT), failed completely to stimulate specific serum antibody titers. Antibody titer experiments were repeated at least twice with similar results (Eliasson et al., 2008).
    • Detailed Gene Information: Click Here.
  • Host Ighg1 response
    • Description: CTA1-M2e-DD elicited a strong IgG1 response. By contrast, soluble M2e-peptide, given even at high doses, 100 μg, together with CTA1-DD (WT), failed completely to stimulate specific serum antibody titers. Antibody titer experiments were repeated at least twice with similar results (Eliasson et al., 2008).
    • Detailed Gene Information: Click Here.
  • Host Ighv1-9 response
    • Description: CTA1-M2e-DD elicited a strong IgG2a response. By contrast, soluble M2e-peptide, given even at high doses, 100 μg, together with CTA1-DD (WT), failed completely to stimulate specific serum antibody titers. Antibody titer experiments were repeated at least twice with similar results (Eliasson et al., 2008).
    • Detailed Gene Information: Click Here.
References
Eliasson et al., 2008: Eliasson DG, El Bakkouri K, Schön K, Ramne A, Festjens E, Löwenadler B, Fiers W, Saelens X, Lycke N. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine. Vaccine. 2008; 26(9); 1243-1252. [PubMed: 18243429].